Carcinoma, Non Small Cell Lung
Conditions
Keywords
non small cell lung cancer, vandetanib, ZD6474, fulvestrant, faslodex, phase 1
Brief summary
The purpose of this study is to evaluate the safety and tolerability of vandetanib and fulvestrant; to find the maximum tolerated dose of these two drugs; and to evaluate response rate and assess toxicity of this combination.
Detailed description
Current treatment for metastatic non-small cell lung cancer (NSCLC) is inadequate, with a median survival of 8-12 months. Second-line therapy options include cytotoxic agents or molecularly-targeted agents such as erlotinib. Nevertheless, only 7-9% of patients will respond to standard second-line treatment. Treatment-related side effects from cytotoxic drugs and declining performance status in patients with progressing disease are significant issues in this patient population. Novel approaches with molecularly-targeted agents are clearly needed. The combination of vandetanib and fulvestrant addresses the potential to interfere with multiple interdependent growth-stimulatory pathways simultaneously. Recent work has revealed cross-talk between epidermal growth factor receptor (EGFR) and estrogen receptor (ER) pathways. This clinical trial will evaluate the clinical interaction of the EGFR inhibitor, vandetanib, in combination with the ER down-regulator, fulvestrant.
Interventions
vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days
DRUGFaslodex (Fulvestrant)
Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.
Sponsors
AstraZeneca
University of Pittsburgh
University of Wisconsin, Madison
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically/histologically confirmed non-small cell lung cancer (NSCLC), advanced (stage IIIB w/ effusion or IV). * Performance status of 0, 1, or 2 * Brain metastases must be clinically stable after treatment with surgery and/or radiotherapy * Must have received two prior systemic anti-cancer regimens for recurrent/ metastatic disease, including one platinum-containing regimen * Prior radiotherapy, chemotherapy and/or treatment with investigational agents is allowed provided that the patient has recovered from the treatment-related side effects to grade ≤1, and that at least 3 weeks has passed since the last dose * Required laboratory values demonstrating adequate bone marrow, kidney, liver, and blood clotting function. * Negative pregnancy test for women of childbearing potential within 7 days prior to study entry * Life expectancy of 3 months or more * Must tolerate intramuscular injections * No prior or concurrent use of estrogen replacement therapy * No concurrent use of cytotoxic, immunologic, hormonal, or investigational agent intended for the antitumor treatment of NSCLC
Exclusion criteria
* Prior therapy with any anti-EGFR therapy such as gefitinib (IRESSA), erlotinib (TARCEVA), vandetanib (ZD6474, ZACTIMA), or fulvestrant (FASLODEX), or an aromatase inhibitor * Clinically significant cardiac event such as myocardial infarction, superior vena cava syndrome, New York Heart Association (NYHA) classification of heart disease ≥ 2 within 3 months before entry * History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation), which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia * Presence of left bundle branch block * Congenital long QT syndrome, or 1st degree relative with unexplained sudden death under 40 years of age * History of QTc prolongation as a result from other medications that required discontinuation of that medication * QTc with Bazett's correction that is unmeasurable, or ≥ 480 msec on screening ECG * Potassium \<4.0 mmol/L despite supplementation, or potassium above the CTCAE grade 1 upper limit * Serum calcium above the CTCAE grade 1 upper limit * Magnesium below the normal range despite supplementation, or above the CTCAE grade 1 upper limit * Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg) * Diagnosis of active interstitial lung disease * Currently active diarrhea that may affect drug absorption * Previous or current malignancies of other histologies within the last 5 years, with the exception of cervical carcinoma in situ and basal cell or squamous cell carcinoma of the skin * Concomitant use of medications that are potent inducers of CYP3A4 are not allowed within 2 weeks of study or during the study * Any unresolved toxicity greater than CTC grade 1 from previous anti-cancer therapy * Major surgery within 4 weeks, or incompletely healed surgical incision * Women who are currently pregnant or breast feeding * History of bleeding diathesis (ie, disseminated intravascular coagulation \[DIC\], clotting factor deficiency) * History of hypersensitivity to active or inactive excipients of fulvestrant (ie castor oil or Mannitol)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Toleration of combination of fulvestrant/vandetanib | Monthly |
Secondary
| Measure | Time frame |
|---|---|
| Response rate to combination of fulvestrant/vandetanib | End of trial |
| Safety of combination of fulvestrant/vandetanib | Monthly |
Outcome results
None listed